Chronic and progressive Parkinson's disease MPTP model in adult and aged mice
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Despite the different animal models of Parkinson's disease developed during the last years, they still present limitations modelling the slow and progressive process of neurodegeneration. Here, we undertook a histological, neurochemical and behavioural analysis of a new chronic parkinsonian mouse model generated by the subcutaneous administration of low doses of MPTP (20 mg/kg, 3 times per week) for 3 months, using both young adult and aged mice. The MPTP‐induced nigrostriatal neurodegeneration was progressive and was accompanied by a decrease in striatal dopamine levels and motor impairment. We also demonstrated the characteristic neuroinflammatory changes (microglial activation and astrogliosis) associated with the neurodegenerative process. Aged animals showed both a faster time course of neurodegeneration and an altered neuroinflammatory response. The long‐term systemic application of low MPTP doses did not induce any increase in mortality in either young adult or aged mice and better resembles the slow evolution of the neurodegenerative process. This treatment could be useful to model different stages of Parkinson's disease, providing a better understanding of the pathophysiology of the disease and facilitating the testing of both protective and restorative treatments. image Here, we show a new chronic and progressive parkinsonian mouse model, in young and aged mice. This model produces a stable degeneration of the dopaminergic nigrostriatal pathway, continuous neuroinflammatory reaction and motor deficits. Aged animals showed a faster neurodegeneration and an altered neuroinflammatory response. This treatment could be useful to model different stages of PD and to test both protective and restorative therapeutic approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
Microglia-mediated neurotoxicity: uncovering the molecular mechanisms
Block, M. L., Zecca, L., & Hong, J.-S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2038 · Cited by 4,110
Kettenmann, H., Hanisch, U.-K., Noda, M., & Verkhratsky, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00011.2010 · Cited by 3,547 · cited 2×
“…response using the general and well established microglial marker, IBA-1, and performed a stereological analysis of total, resting and activated micro- glial cells based on the soma cell volume and the characteristic morphology of active microglia (Block et al. 2007; Kettenmann et al. 2011).”
BackgroundMethodMcGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Neuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984
The efficiency of systematic sampling in stereology—reconsidered
GUNDERSEN, H. J. G., JENSEN, E. B. V., KIÊU, K., & NIELSEN, J. (1999) · Journal of Microscopy · doi:10.1046/j.1365-2818.1999.00457.x · Cited by 1,317
New stereological methods for counting neurons
West, M. J. (1993) · Neurobiology of Aging · doi:10.1016/0197-4580(93)90112-o · Cited by 940
Toxin-induced models of Parkinson’s disease
Bové, J., Prou, D., Perier, C., & Przedborski, S. (2005) · NeuroRX · doi:10.1602/neurorx.2.3.484 · Cited by 739 · cited 1×
“…models present pitfalls regarding the mortality rate of treated animals, the appearance of significant non-dopaminergic lesions and, in the case of the proteasome inhibitor model, lack of reproducibility (Bov e et al. 2005, 2006; Kordower et al. 2006; Cicchetti et al. 2009; Bov e and Perier 2012).”
BackgroundGlial reactions in Parkinson's disease
McGeer, P. L., & McGeer, E. G. (2008) · Movement Disorders · doi:10.1002/mds.21751 · Cited by 701
Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease
McNaught, K. S. P., Perl, D. P., Brownell, A., & Olanow, C. W. (2004) · Annals of Neurology · doi:10.1002/ana.20186 · Cited by 548
Cited by
Lai, F., Jiang, R., Xie, W., Liu, X., Tang, Y., Xiao, H., Gao, J., Jia, Y., & Bai, Q. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2620-x · Cited by 169
Zhang, Y., He, X., Wu, X., Lei, M., Wei, Z., Zhang, X., Wen, L., Xu, P., Li, S., & Qu, S. (2017) · Cell Death & Disease · doi:10.1038/cddis.2016.491 · Cited by 66
Capucciati, A., Zucca, F. A., Monzani, E., Zecca, L., Casella, L., & Hofer, T. (2021) · Antioxidants · doi:10.3390/antiox10060824 · Cited by 36
“However, since MPTP was potent also in young adult mice [71,72], this indicates that MPTP also targets dopaminergic neurons lacking NM, at least at higher doses.”
BackgroundMouse models of neurodegenerative disease: preclinical imaging and neurovascular component
Albanese, S., Greco, A., Auletta, L., & Mancini, M. (2018) · Brain Imaging and Behavior · doi:10.1007/s11682-017-9770-3 · Cited by 16
Metadata
- Authors
- Muñoz‐Manchado, A. B., Villadiego, J., Romo‐Madero, S., Suárez‐Luna, N., Bermejo‐Navas, A., Rodríguez‐Gómez, J. A., Garrido‐Gil, P., Labandeira‐García, J. L., Echevarría, M., López‐Barneo, J., & Toledo‐Aral, J. J.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2015-11-24
- Volume
- 136
- Issue
- 2
- Pages
- 373-387
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2163543612
- Cited by
- 92
- References
- 11
- FWCI
- 4.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chronic and progressive Parkinson's disease MPTP model in adult and aged mice. https://app.cochat.ai/papers/10.1111/jnc.13409
- The paper
- Muñoz‐Manchado, A. B., Villadiego, J., Romo‐Madero, S., Suárez‐Luna, N., Bermejo‐Navas, A., Rodríguez‐Gómez, J. A., Garrido‐Gil, P., Labandeira‐García, J. L., Echevarría, M., López‐Barneo, J., & Toledo‐Aral, J. J. (2016). Chronic and progressive Parkinson's disease MPTP model in adult and aged mice. Journal of Neurochemistry. https://doi.org/10.1111/jnc.13409
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.